Shots:

• The NDA is based on P-III OPTIMUM study assessing ponesimod (20mg) vs Aubagio (teriflunomide- 14 mg) in patients with relapsing MS
• The P-III OPTIMUM study results: reduction in ARR (30.5%); reduction in CUALs (56%); reduction in fatigue symptoms; safety profile is consistent with the previous studies
• Ponesimod is an investigational S1P1 modulator- act by inhibiting the S1P protein activity and has the potential to reduce the number of circulating lymphocytes crossing BBB

Click here ­to­ read full press release/ article 

Ref: J&J | Image: Janssen